Opticyte has been capital-efficient and is funded for the next year with a non-dilutive grant. The company has issued patents, a clear De Novo pathway, and the potential to deliver significant cost savings to hospitals. Demonstrating strong momentum and credibility, Opticyte is a medical device innovator to watch.
The company is currently raising Series A. Milestones include product development, FDA clearance, and execution of a multi-center randomized controlled trial.